MedMira Announces Annual Shareholders Meeting Results

HALIFAX, NOVA SCOTIA--(Marketwired - Feb. 1, 2016) - MedMira Inc. (MedMira) (TSX VENTURE:MIR) held its 2016 Annual General and Special Meeting of Shareholders on January 29, 2016. Incumbent Directors Mr. Hermes Chan, Mr. Marvyn Robar, and Mr. Romano Robusto were re-elected. Dr. Philippe Dro, the OnSite Lab Holdings AG representative, and Dr. Martial Lacroix were newly elected to the MedMira Board of Directors.

Mr. Robar remains as Chairman of the Board. Dr. Colin MacGillivray chose not stand for re-election and the Company thanks him for his service as a Director. Shareholders also approved an amended stock option plan and the appointment of Deloitte LLP as the Company's auditors during the meeting held in Halifax, N.S.

"Dr. Lacroix is a welcome addition to MedMira's Board," said Marvyn Robar, Chairman of the Board, MedMira Inc. "His in-depth experience and background in the diagnostics industry and fund management sector will be a valuable contribution to the Board as we continue to provide the Company with proactive and strategic oversight."

Dr. Lacroix brings extensive experience to the Board in his roles as a diagnostic industry expert and venture fund executive in the technology and therapeutics fields. He currently holds the positions of General Partner of AgeChem Financial Inc. and of AmorChem Financial Inc. Over the last 17 years, Dr. Lacroix has managed four funds, including the $100 million GeneChem Technology Venture Fund L.P., dedicated to making investments in companies involved in the areas of genomics and proteomics, as well as GeneChem Therapeutics Venture Fund L.P., AgeChem Venture Fund L.P., and AmorChem Venture Fund L.P. Prior to this, Dr. Lacroix, a co-founder of IAF BioChem, Inc. (later named BioChem Pharma, Inc.) was Director R&D of BioChem ImmunoSystems Inc., the diagnostics division of BioChem Pharma, where his team developed diagnostic kits that were sold in Canada, Europe and South America. Dr. Lacroix earned a B.Sc. and M.Sc. in biochemistry at the Université de Montréal, a Ph.D. in biochemistry and molecular endocrinology from University of Toronto, and conducted his post-doctoral studies in virology at Institut Armand-Frappier in Laval, Quebec.

About MedMira

MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technologyä. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Revealâ, Multiplo™ and Miriad™ brands in global markets. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in Atlanta, Georgia, United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.